Drug Name Premarin

Flomax, Alna, Josir, Pradif, Secotex, Urolosin, Mecir (tamsulosin). Indicated for the treatment of Lower urinary tract Symptoms (LUTS) associated with benign prostate hyperplasia and available since 1996 as capsule controlled release formulation in the main world markets. Starting in 2005, a new tablet formulation based on the OCAS (Oral Controlled Absorption System) technology has been made available in many European markets and in Canada.
It was first marketed by Eli Lilly and Company, and it is today commonly known as EES (erythromycin ethylsuccinate, an ester prodrug that is commonly administered). In structure, this macrocyclic compound contains a 14-membered lactone ring with ten asymmetric centers and two sugars (L-cladinose and D-desosamine), making it a compound very difficult to produce via synthetic methods.

 

On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended. Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.
CELEBREX is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.